SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun jumps on getting USFDA’s nod for Ranitidine Tablets

24 Aug 2016 Evaluate

Strides Shasun is currently trading at Rs 972.40, up by 14.85 points or 1.55% from its previous closing of Rs 957.55 on the BSE.

The scrip opened at Rs. 961.00 and has touched a high and low of Rs. 981.00 and Rs. 957.00 respectively. So far 501337 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs 1,052.45 and Rs. 948.20 respectively. The current market cap of the company is Rs. 8668.50 crore.

The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 47.98% and 20.89% respectively.

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Ranitidine Tablets USP, 150 mg and 300 mg. Ranitidine tablet is the first integrated product approval where the API and formulations will be manufactured at erstwhile Shasun Pharmaceutical's Cuddalore and Pondicherry facilities respectively.

The US market for Ranitidine Tablets USP, 150 mg and 300 mg is around $125 Million. The product to be launched immediately will be marketed by Strides Pharma Inc in the US Market.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

997.65 1.75 (0.18%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×